Baruch Baluku, JosephBongomin, Felix2023-11-252023-11-252021-02-06Baluku, J. B., & Bongomin, F. (2021). Treatment outcomes of pregnant women with drug-resistant tuberculosis in Uganda: a retrospective review of 18 cases. International Journal of Infectious Diseases, 105, 230-233.https://doi.org/10.1016/j.ijid.2021.02.032http://www.elsevier.com/locate/ijidhttps://hdl.handle.net/20.500.14270/359Background: There is a dearth of reports on drug-resistant tuberculosis (DRTB) treatment outcomes among pregnant women in tuberculosis (TB)/HIV high-burdened countries. We report treatment outcomes of 18 pregnant women with DRTB in Uganda. Methods: We reviewed charts of individuals who received DRTB treatment in Uganda across 16 DRTB treatment sites. We included all women who were pregnant during DRTB treatment and had a treatment outcome documented between 2013 and 2019. Results: There were 18 pregnant women with a mean age (standard deviation (SD)) of 27.5 (5.2) years, of whom 8 (44.4%) were HIV co-infected. Among these women, 12 (66.7%) had primary DRTB and 8 (44.4%) had multidrug-resistant TB. Levofloxacin (Lfx), Pyrazinamide, Cycloserine and Kanamycin (Kn) were the most (>78%) used drugs in the treatment regimen and the mean (SD) treatment duration was 17.6 (7.5) months. Elevated liver enzymes (81.8%, n = 11) and hearing loss (33.3%, n = 15) were the most frequently encountered drug adverse events. Treatment success was observed among 15 (83.3%) patients, 2 (11.1%) patients were lost to follow up and 1 (5.6%) patient died. Conclusion: The treatment success among pregnant women with DRTB in Uganda was high despite a high prevalence of HIV co-infection.enDrug-resistant tuberculosisMDR TBPregnancyUgandaHIVWomenArticle